S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61

Sarepta Therapeutics Stock Forecast, Price & News

+3.40 (+4.73%)
(As of 06/24/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
1.74 million shs
Average Volume
584,055 shs
Market Capitalization
$6.58 billion
P/E Ratio
Dividend Yield
Price Target
30 days | 90 days | 365 days | Advanced Chart

Receive SRPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SRPT Stock Forecast (MarketRank)

Overall MarketRank

2.14 out of 5 stars

Medical Sector

443rd out of 1,417 stocks

Pharmaceutical Preparations Industry

186th out of 675 stocks

Analyst Opinion: 3.4Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
Sarepta Therapeutics logo

About Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

SRPT Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Previous Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
13 Analysts


Net Income
$-418.78 million
Pretax Margin


Sales & Book Value

Annual Sales
$701.89 million
Book Value
$10.66 per share


Free Float
Market Cap
$6.58 billion

Sarepta Therapeutics Frequently Asked Questions

Should I buy or sell Sarepta Therapeutics stock right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sarepta Therapeutics in the last year. There are currently 3 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" Sarepta Therapeutics stock.
View analyst ratings for Sarepta Therapeutics
or view top-rated stocks.

What is Sarepta Therapeutics' stock price forecast for 2022?

13 Wall Street analysts have issued 12 month price targets for Sarepta Therapeutics' shares. Their SRPT stock forecasts range from $74.00 to $155.00. On average, they anticipate Sarepta Therapeutics' stock price to reach $119.25 in the next year. This suggests a possible upside of 58.5% from the stock's current price.
View analysts' price targets for Sarepta Therapeutics
or view top-rated stocks among Wall Street analysts.

How has Sarepta Therapeutics' stock performed in 2022?

Sarepta Therapeutics' stock was trading at $90.05 at the beginning of 2022. Since then, SRPT shares have decreased by 16.5% and is now trading at $75.22.
View the best growth stocks for 2022 here

When is Sarepta Therapeutics' next earnings date?

Sarepta Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for Sarepta Therapeutics

How were Sarepta Therapeutics' earnings last quarter?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) posted its quarterly earnings results on Wednesday, May, 4th. The biotechnology company reported ($1.20) earnings per share for the quarter, topping the consensus estimate of ($1.35) by $0.15. The biotechnology company had revenue of $210.83 million for the quarter, compared to analyst estimates of $208.25 million. Sarepta Therapeutics had a negative trailing twelve-month return on equity of 52.06% and a negative net margin of 46.56%. Sarepta Therapeutics's quarterly revenue was up 43.5% on a year-over-year basis. During the same period in the prior year, the business earned ($2.10) EPS.
View Sarepta Therapeutics' earnings history

What guidance has Sarepta Therapeutics issued on next quarter's earnings?

Sarepta Therapeutics issued an update on its FY 2022 earnings guidance on Tuesday, March, 29th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $880 M-, compared to the consensus revenue estimate of $908.46 million.

Who are Sarepta Therapeutics' key executives?

Sarepta Therapeutics' management team includes the following people:
  • Mr. Douglas S. Ingram Esq., Pres, CEO & Director (Age 59, Pay $1.55M) (LinkedIn Profile)
  • Mr. Ian Michael Estepan, Exec. VP & CFO (Age 46, Pay $861.75k)
  • Mr. William F. Ciambrone, Exec. VP of Technical Operations (Age 58, Pay $780.28k)
  • Dr. Louise R. Rodino-Klapac Ph.D., Exec. VP, Chief Scientific Officer and Head of R&D (Age 44, Pay $929.68k) (LinkedIn Profile)
  • Mr. Ryan E. Brown, Sr. VP, Gen. Counsel & Corp. Sec. (Age 44, Pay $913.64k)
  • Mary Jenkins, Sr. Mang. of Investor Relations
  • Ms. Alison Nasisi, Chief People Officer & VP
  • Dr. Diane L. Berry, Sr. VP of Global Health Policy and Gov. & Patient Affairs
  • Mr. Dallan Murray, Sr. VP & Chief Customer Officer
  • Mr. Joseph Bratica, Controller & VP (Age 58) (LinkedIn Profile)

What is Douglas S. Ingram's approval rating as Sarepta Therapeutics' CEO?

15 employees have rated Sarepta Therapeutics CEO Douglas S. Ingram on Glassdoor.com. Douglas S. Ingram has an approval rating of 95% among Sarepta Therapeutics' employees. This puts Douglas S. Ingram in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Sarepta Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sarepta Therapeutics investors own include Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV) and Walt Disney (DIS).

What is Sarepta Therapeutics' stock symbol?

Sarepta Therapeutics trades on the NASDAQ under the ticker symbol "SRPT."

Who are Sarepta Therapeutics' major shareholders?

Sarepta Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.50%), Sands Capital Management LLC (5.47%), Wellington Management Group LLP (3.06%), Bellevue Group AG (1.32%), Farallon Capital Management LLC (1.13%) and Goldman Sachs Group Inc. (1.06%). Company insiders that own Sarepta Therapeutics stock include Alexander Cumbo, David T Howton, Douglas S Ingram, Hans Lennart Rudolf Wigzell, Joseph Bratica, Louise Rodino-Klapac, M Kathleen Behrens, Michael W Bonney, Richard Barry and Sandesh Mahatme.
View institutional ownership trends for Sarepta Therapeutics

Which institutional investors are selling Sarepta Therapeutics stock?

SRPT stock was sold by a variety of institutional investors in the last quarter, including Sands Capital Management LLC, Victory Capital Management Inc., Zurcher Kantonalbank Zurich Cantonalbank , Goldman Sachs Group Inc., Tekla Capital Management LLC, Renaissance Technologies LLC, JPMorgan Chase & Co., and Simplex Trading LLC. Company insiders that have sold Sarepta Therapeutics company stock in the last two years include Hans Lennart Rudolf Wigzell, Joseph Bratica, M Kathleen Behrens, and Richard Barry.
View insider buying and selling activity for Sarepta Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Sarepta Therapeutics stock?

SRPT stock was purchased by a variety of institutional investors in the last quarter, including American Century Companies Inc., Wellington Management Group LLP, Bank of Montreal Can, Prudential Financial Inc., Assenagon Asset Management S.A., Bellevue Group AG, Allspring Global Investments Holdings LLC, and Farallon Capital Management LLC. Company insiders that have bought Sarepta Therapeutics stock in the last two years include Douglas S Ingram, and Louise Rodino-Klapac.
View insider buying and selling activity for Sarepta Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Sarepta Therapeutics?

Shares of SRPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sarepta Therapeutics' stock price today?

One share of SRPT stock can currently be purchased for approximately $75.22.

How much money does Sarepta Therapeutics make?

Sarepta Therapeutics (NASDAQ:SRPT) has a market capitalization of $6.58 billion and generates $701.89 million in revenue each year. The biotechnology company earns $-418.78 million in net income (profit) each year or ($4.24) on an earnings per share basis.

How many employees does Sarepta Therapeutics have?

Sarepta Therapeutics employs 840 workers across the globe.

How can I contact Sarepta Therapeutics?

Sarepta Therapeutics' mailing address is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. The official website for Sarepta Therapeutics is www.sareptatherapeutics.com. The biotechnology company can be reached via phone at (857) 242-4000, via email at [email protected], or via fax at 425-354-5038.

This page (NASDAQ:SRPT) was last updated on 6/26/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.